This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Suspect & Detect About ATTR-CM Study Design Efficacy & Safety Profile Dosing MOD/MOA Important Safety Information Abbreviated Prescribing Information
Important Safety Information


VYNDAMAX™ is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.1

Dosage and administration

The recommended dosage of VYNDAMAX™ 61 mg (one 61-mg tafamidis capsule) orally once daily. The capsules should be swallowed whole and not crushed or cut. If a dose is missed, instruct patients to take the dose as soon as remembered or to skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose. No clinically significant differences in the pharmacokinetics of tafamidis were observed following administration of a high fat, high calorie meal.1

Contraindications: None.1

Adverse Reactions:

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with tafamidis was similar to placebo.1

Specific Populations 

Pregnancy: VYNDAMAX™ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes.1


Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with VYNDAMAX™.1

MOA: mechanism of action; MOD: mechanism of disease.

MOA: mechanism of action; MOD: mechanism of disease.

References:VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.

MOH Approval No. : HF0098OA171/082022

Invalidation Date : 11/08/2024


Support & Services

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No